major depressive disorder
Seaport Therapeutics doses first patient in trial of GlyphAllo for depression
July 25, 2025Research and Development Psychiatry, Seaport Therapeutics, clinical trial, major depressive disorder, mental health, neuropsychiatric conditions
Seaport Therapeutics has dosed its first patient in its phase 2b BUOY-1 study of GlyphAllo (SPT-300), an oral prodrug of …
Smartphone app for treating depression launches in UK
June 17, 2025Clinical & Scientific, Freelancers NHS trusts, Psychiatry, Rejoyn, digital therapeutics, major depressive disorder, mental health
Otsuka and Click Therapeutics have launched Rejoyn, a prescription digital therapeutic for major depressive disorder (MDD), in the UK. The …
Abbvie acquires Cerevel Therapeutics
August 2, 2024Mergers and Acquisitions AbbVie, Cerevel Therapeutics, Drug-Resistant Epilepsy, Neurology, Parkinson's disease, major depressive disorder, mergers & acquisitions, neurology, neuroscience, schizophrenia
Abbvie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline. Cerevel has multiple programmes across neurological and psychiatric …
Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy
April 17, 2024Research and Development Intra-Cellular Therapies, Neurology, clinical trial, major depressive disorder, mental health
Intra-Cellular Therapies has announced positive topline results from Study 501, which assessed lumateperone 42mg as an adjunctive therapy to antidepressants …
Acadia’s pimavanserin falls short at Phase 3 in major depressive disorder
July 21, 2020Manufacturing and Production, Research and Development Acadia Pharmaceuticals, major depressive disorder, phase 3, trial failure
Acadia Pharmaceuticals has lifted the lid on new Phase 3 for its therapy pimavanserin, revealing that the drug unfortunately failed …
Sage Therapeutics’ depression drug falls short at Phase 3
December 6, 2019Medical Communications, Research and Development Sage Therapeutics, major depressive disorder, pharma, trial failure
Sage Therapeutics has announced that its candidate SAGE-217 flopped in Phase 3 trials investigating its efficacy in symptom reduction for …
FDA fast-tracks psilocybin treatment for major depressive disorder
November 25, 2019Sales and Marketing Controlled Substance Act, FDA, breakthrough therapy, major depressive disorder, psilocybin
The FDA has granted a Breakthrough Therapy designation to the Usona Institute for its trial use of psilocybin in the …
Lundbeck and Takeda’s depression drug approved in Japan
September 20, 2019Medical Communications, Sales and Marketing Japan, Lundbeck, Takeda, major depressive disorder, pharma
Takeda and Lundbeck have announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has chosen to authorise their drug …
Janssen’s argues for the cost-effectiveness of Spravato in treatment-resistant depression
May 23, 2019Sales and Marketing FDA, Janssen, depression, major depressive disorder, pharma, treatment-resistant depression
Janssen has unveiled a new cost-effectiveness analysis for its recently FDA-approved nasal spray Spravato (esketamine) in the treatment of treatment-resistant …
Allergan’s depression drug rapastinel fails to outperform placebo at Phase 3
March 7, 2019Research and Development Allergan, FDA, depression, major depressive disorder, pharma, rapastinel
As Janssen celebrated the FDA approval of the first novel therapy for depression in three decades with Spravato, Allergan released …
Janssen’s esketamine drug recommended by FDA panel for depression
February 13, 2019Research and Development, Sales and Marketing FDA, Janssen, Spravato, depression, esketamine, major depressive disorder, pharma
In a rare and welcomed development in the treatment of major depressive disorder (MDD), Janssen has announced that its esketamine …
FDA knocks back Alkermes’ opioid-based depression therapy over lack of evidence
February 4, 2019Sales and Marketing Alkermes, FDA, major depressive disorder, pharma, rejection
Alkermes experimental opioid-based depression therapy ALKS 5461 has been rejected by the FDA, it has emerged, in the adjunctive treatment …
Alkermes sent reeling as FDA refuses review of depression treatment
April 3, 2018Manufacturing and Production, Research and Development, Sales and Marketing Alkermes, FDA, depression, major depressive disorder, pharma
Alkermes shares were knocked down to their lowest level since October 2016 after it was revealed that the FDA had …
Phase III depression trial success for Alkermes
October 24, 2016Research and Development, Sales and Marketing ALKS 5461, Alkermes, major depressive disorder
Biopharma company Alkermes has announced the success of its ALKS 5461 treatment in a Phase III study for the treatment …
FDA approves Lundbeck and Otsuka’s Rexulti for depression
July 14, 2015Sales and Marketing FDA, Lundbeck, Otsuka, Rexulti, US, brexpiprazole, depression, major depressive disorder, schizophrenia
Lundbeck and Otsuka have gained a yes vote from the FDA for their jointly-marketed antidepressant, Rexulti. The US regulator approved …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
